ENLV logo

Enlivex Therapeutics Ltd.

ENLV
Healthcare|Biotechnology|IL
$1.27
+0.00 (+0.00%)
Tangible Book / Share
$2661.47
Graham Number
$18359.01
Cash / Share
$5.34
Next Earnings Report
Nov 13, 2026
EPS est. -$4.48
Financing Filings (last 12 months)
8
Shelf registrations / offering prospectuses — latest Aug 17, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (1)

Feb 2027
Est. completion
P2Primary Knee Osteoarthritis
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716n=182

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026
Early P1
Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety
NCT06208241

Recent Press Releases

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
Nov 2, 2026 · GlobeNewsWire
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Oct 28, 2026 · GlobeNewsWire
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Oct 27, 2026 · GlobeNewsWire
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Oct 22, 2026 · GlobeNewsWire
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Oct 19, 2026 · GlobeNewsWire
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Sep 22, 2026 · GlobeNewsWire

SEC Filings (88)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 2, 20266-KForeign issuer reportDocumentIndex
Oct 28, 20266-KForeign issuer reportDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Oct 22, 20266-KForeign issuer reportDocumentIndex
Oct 19, 20266-KForeign issuer reportDocumentIndex
Oct 2, 20266-K/AForeign issuer reportDocumentIndex
Oct 1, 20266-K/AForeign issuer reportDocumentIndex
Sep 29, 20266-KForeign issuer reportDocumentIndex
Sep 25, 20266-KForeign issuer reportDocumentIndex
Sep 22, 20266-KForeign issuer reportDocumentIndex
Aug 17, 2026424B3Offering prospectusDocumentIndex
Aug 13, 2026EFFECTDocumentIndex
Aug 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 11, 20266-KForeign issuer reportDocumentIndex
Aug 6, 2026F-3Shelf registrationDocumentIndex
Jul 30, 20266-KForeign issuer reportDocumentIndex
Jul 29, 20266-KForeign issuer reportDocumentIndex
Jul 28, 20266-KForeign issuer reportDocumentIndex
Jul 28, 20266-KForeign issuer reportDocumentIndex
Jul 20, 20266-KForeign issuer reportDocumentIndex
Jul 13, 20266-KForeign issuer reportDocumentIndex
Jul 7, 20266-KForeign issuer reportDocumentIndex
Jun 24, 20266-KForeign issuer reportDocumentIndex
Jun 22, 20266-KForeign issuer reportDocumentIndex
May 28, 20266-KForeign issuer reportDocumentIndex
May 27, 20266-KForeign issuer reportDocumentIndex
May 18, 20266-KForeign issuer reportDocumentIndex
May 15, 20266-KForeign issuer reportDocumentIndex
May 1, 2026424B3Offering prospectusDocumentIndex
Apr 21, 2026F-3Shelf registrationDocumentIndex
Apr 21, 20266-KForeign issuer reportDocumentIndex
Apr 8, 20266-KForeign issuer reportDocumentIndex
Mar 26, 20266-KForeign issuer reportDocumentIndex
Mar 25, 202620-FAnnual report (foreign)DocumentIndex
Mar 25, 20266-KForeign issuer reportDocumentIndex
Mar 24, 20266-KForeign issuer reportDocumentIndex
Mar 23, 20266-KForeign issuer reportDocumentIndex
Mar 20, 2026424B3Offering prospectusDocumentIndex
Mar 13, 2026S-8Employee stock planDocumentIndex
Feb 23, 20266-KForeign issuer reportDocumentIndex